-
Although the incidence of catheter-related bloodstream infections from arterial catheters is low, arterial catheters have similar colonization rates and catheter-related bloodstream infections as concurrently sited and identically managed central venous catheters.
-
Life Recovery Systems (Alexandria, Louisiana) reported FDA approval of an Investigational Device Exemption (IDE) application to investigate rapid hypothermia treatment in combination with primary angioplasty to treat heart attacks.
-
Drug eluting stents (DES) wire mesh tubes that prop open a previously blocked artery to the heart have gone a long way toward reducing restenosis in cardiac patients after percutaneous coronary intervention. But they've also created a host of potential complications from impairing imaging to hindering surgical revascularization or positive remodeling (an increase in arterial area).
-
Michael Mussallem, CEO and chairman of Edwards Lifesciences, (Irvine, California), has been named chairman of AdvaMed (Washington). He succeeds Edward Ludwing, president/CEO and chairman of BD (Franklin Lakes, New Jersey), who has led the organization for the past two years.
-
The FDA has placed a large speed bump in front of the plans for a confirmatory clinical trial by Vasogen (Mississauga, Ontario) for its heart failure treatment.
-
Royal Philips Electronics (Amsterdam, the Netherlands) reported that it will lead a new European Union (EU)-funded research project aimed at improving care of heart patients through the development of telemonitoring solutions. The HeartCycle project, which follows the MyHeart project in the EU, was launched on March 1, and will be one of the largest biomedical and healthcare research projects within the EU, according to Philips.
-
A team of researchers at Oregon Health & Science University (OHUSU; Eugene) and Washington University (St. Louis) say they have described for the first time the mechanism that gives a mutant enzyme molecule that they have engineered and patented with potential to become a breakthrough drug for treating heart attacks and strokes.
-
Stem Cell Therapeutics (SCT; Calgary, Alberta) at this year's Stroke meeting reported favorable results from its Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital (Newport Beach, California).
-
In this paper, corrado and colleagues describe the results of endocardial voltage mapping (EVM) and endomyocardial biopsy (EMB) in 27 patients with ventricular arrhythmias who were suspected to have a subtle manifestation of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
-
Clinical features of flash pulmonary edema (PE) are poorly understood. Thus, Dal-Bianco and colleagues from the Mayo Clinic studied the records of patients coded as pulmonary edema and identified 37 patients who had first-time flash PE and an echocardiogram and a BNP level within 24 hours.
